Disease Management's Infinite Variety
Executive SummaryDisease management is one of those concepts that means pretty much whatever you want it to mean. To give some sense of the variety, we've collected some recent disease management deals.
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.